東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Chemistry and pharmacology of drug d...

Li, Jie Jack.

FindBook

Google Book

Amazon

博客來

Chemistry and pharmacology of drug discovery /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Chemistry and pharmacology of drug discovery // edited by Jie Jack Li.
其他作者:	Li, Jie Jack.
出版者:	Hoboken, New Jersey :John Wiley & Sons, Inc., : c2025.,
面頁冊數:	418 p. :ill. (some col.) ;26 cm.
標題:	Drug development. -
ISBN:	9781394225125

Chemistry and pharmacology of drug discovery /
Chemistry and pharmacology of drug discovery /edited by Jie Jack Li. - Hoboken, New Jersey :John Wiley & Sons, Inc.,c2025. - 418 p. :ill. (some col.) ;26 cm.

Includes bibliographical references and index.

Chemistry and Pharmacology of Drug Discovery illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines, discussing a total of 20 drugs that are all FDA-approved post 2021 - some of which are first-in-class and revolutionary. The four sections in this book cover Infectious Disease, Cancer Drugs, CNS Drugs, and Miscellaneous Drugs. Each chapter covers background material on the drug class and/or disease indication and key aspects relevant to the discovery of the drug, including structure-activity relationships, pharmacokinetics, drug metabolism, efficacy, and safety. This book is contributed to by various veterans and well-known experts in medical chemistry, many of whom discovered the drugs they reviewed, leading to tremendous quality and depth of insight. Some of the drugs covered in Chemistry and Pharmacology of Drug Discovery include: Nirmatrelvir (Paxlovid with Ritonavir), a 3-chymotrypsin-like protease inhibitor for treating SARS-CoV-2 infection; Doravirine (Pifeltro), a third-generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection; Oteseconazole (Vivjoa), a CYP51 inhibitor for treating recurrent vulvovaginal candidiasis, and Rimegepant (Nurtec ODT), a CGRP antagonist for treating migraine; Ciprofol (Cipepofol), a γ-Aminobutyric acid receptor agonist for induction of anesthesia, and Ozanimod (Zeposia), an S1P receptor antagonist for treating multiple sclerosis; Deucravacitinib (Sotyktu), a first-in-class deuterated TYK2 inhibitor for the treatment of plaque psoriasis.

ISBN: 9781394225125US195.00Subjects--Topical Terms:

716904
Drug development.

LC Class. No.: RM301.25 / .C44 2025

Dewey Class. No.: 615.1/9

Chemistry and pharmacology of drug discovery /
LDR:02184cam a2200157 a 4500 001 2367333
008 241125s2025 njua b 001 0 eng d
020 $a 9781394225125 $q (hbk.) : $c US195.00
035 $a (OCoLC)1452269847
040 $a OCLKB $b eng $e aacr2 $e pn $c OCLKB $d EBLCP $d YDX $d OCLCO $d N$T $d DG1
050 # 4 $a RM301.25 $b .C44 2025
082 0 4 $a 615.1/9 $2 23/eng/20240823
245 0 0 $a Chemistry and pharmacology of drug discovery / $c edited by Jie Jack Li.
260 # $a Hoboken, New Jersey : $b John Wiley & Sons, Inc., $c c2025.
300 $a 418 p. : $b ill. (some col.) ; $c 26 cm.
504 $a Includes bibliographical references and index.
520 # $a Chemistry and Pharmacology of Drug Discovery illustrates how chemistry, biology, pharmacokinetics, and a host of disciplines come together to produce successful medicines, discussing a total of 20 drugs that are all FDA-approved post 2021 - some of which are first-in-class and revolutionary. The four sections in this book cover Infectious Disease, Cancer Drugs, CNS Drugs, and Miscellaneous Drugs. Each chapter covers background material on the drug class and/or disease indication and key aspects relevant to the discovery of the drug, including structure-activity relationships, pharmacokinetics, drug metabolism, efficacy, and safety. This book is contributed to by various veterans and well-known experts in medical chemistry, many of whom discovered the drugs they reviewed, leading to tremendous quality and depth of insight. Some of the drugs covered in Chemistry and Pharmacology of Drug Discovery include: Nirmatrelvir (Paxlovid with Ritonavir), a 3-chymotrypsin-like protease inhibitor for treating SARS-CoV-2 infection; Doravirine (Pifeltro), a third-generation non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection; Oteseconazole (Vivjoa), a CYP51 inhibitor for treating recurrent vulvovaginal candidiasis, and Rimegepant (Nurtec ODT), a CGRP antagonist for treating migraine; Ciprofol (Cipepofol), a γ-Aminobutyric acid receptor agonist for induction of anesthesia, and Ozanimod (Zeposia), an S1P receptor antagonist for treating multiple sclerosis; Deucravacitinib (Sotyktu), a first-in-class deuterated TYK2 inhibitor for the treatment of plaque psoriasis.
650 # 0 $a Drug development. $3 716904
700 1 # $a Li, Jie Jack. $3 726220